In line with our results, it has been shown that combined treatment of the AKT inhibitor perifosine and the AMPK activator AICAR, markedly suppressed prostate PC3 cell growth compared to either treatment alone which indicates that concurrent modulation of AKT and AMPK is more effective than either alone in prostate cancer therapy [30]. This evidence concerns the gene AKT1 and Familial prostate cancer.